Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
8.23
-0.46 (-5.29%)
Nov 18, 2026, 4:00 PM EST - Market closed
Enanta Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Cash & Equivalents | 20.27 | 32.3 | 37.23 | 85.39 | 43.99 |
Short-Term Investments | 174.24 | 156.57 | 210.95 | 284.52 | 205.24 |
Cash & Short-Term Investments | 194.51 | 188.86 | 248.19 | 369.91 | 249.23 |
Cash Growth | 2.99% | -23.90% | -32.91% | 48.42% | 2.14% |
Accounts Receivable | 5.86 | 6.88 | 6.65 | 8.61 | 20.32 |
Other Receivables | - | - | 32 | 31 | 28.72 |
Receivables | 5.86 | 6.88 | 38.65 | 39.62 | 49.04 |
Prepaid Expenses | 5.63 | 8.59 | 12.41 | 13.26 | 13.45 |
Restricted Cash | - | - | 0.61 | - | - |
Total Current Assets | 205.99 | 204.34 | 299.85 | 422.79 | 311.71 |
Property, Plant & Equipment | 66.11 | 72.94 | 73.35 | 34.71 | 29.75 |
Long-Term Investments | - | - | - | - | 29.29 |
Other Long-Term Assets | 3.48 | 3.45 | 3.45 | 4.77 | 4.66 |
Total Assets | 275.58 | 280.73 | 376.65 | 462.28 | 375.41 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Accounts Payable | 2.75 | 1.95 | 8 | 4.1 | 6 |
Accrued Expenses | 14.69 | 12.75 | 13.55 | 18.34 | 20.94 |
Current Portion of Long-Term Debt | 32.97 | 30.71 | 34.46 | 35.08 | - |
Current Portion of Leases | 4.06 | 3.15 | 1.52 | 5.28 | 2.89 |
Total Current Liabilities | 54.46 | 48.56 | 57.54 | 62.79 | 29.83 |
Long-Term Debt | 89.93 | 112.44 | 136.13 | 160.85 | 1.42 |
Long-Term Leases | 50.7 | 54.76 | 53.94 | 21.24 | 22.37 |
Other Long-Term Liabilities | 0.3 | 0.26 | 0.23 | 0.66 | 0.45 |
Total Liabilities | 195.38 | 216.02 | 247.84 | 245.54 | 54.08 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Common Stock | 80.2 | 0.21 | 0.21 | 0.21 | 0.21 |
Additional Paid-In Capital | - | 469.77 | 451.34 | 424.69 | 398.03 |
Retained Earnings | - | -404.93 | -323.04 | -207 | -73.18 |
Comprehensive Income & Other | - | -0.34 | 0.3 | -1.17 | -3.72 |
Shareholders' Equity | 80.2 | 64.72 | 128.81 | 216.74 | 321.33 |
Total Liabilities & Equity | 275.58 | 280.73 | 376.65 | 462.28 | 375.41 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Total Debt | 177.65 | 201.06 | 226.06 | 222.44 | 26.69 |
Net Cash (Debt) | 16.86 | -12.19 | 22.13 | 147.47 | 251.83 |
Net Cash Growth | - | - | -85.00% | -41.44% | -27.13% |
Net Cash Per Share | 0.58 | -0.57 | 1.05 | 7.03 | 12.22 |
Filing Date Shares Outstanding | 29.13 | 28.86 | 21.19 | 21.06 | 20.8 |
Total Common Shares Outstanding | 29.13 | 21.39 | 21.19 | 21.06 | 20.79 |
Working Capital | 151.53 | 155.78 | 242.32 | 360 | 281.89 |
Book Value Per Share | 2.75 | 3.03 | 6.08 | 10.29 | 15.46 |
Tangible Book Value | 80.2 | 64.72 | 128.81 | 216.74 | 321.33 |
Tangible Book Value Per Share | 2.75 | 3.03 | 6.08 | 10.29 | 15.46 |
Machinery | - | 20.39 | 19.92 | 19.14 | 16.79 |
Construction In Progress | - | - | 22.75 | 1.27 | 2.56 |
Leasehold Improvements | - | 38.2 | 13.98 | 13.8 | 7.28 |